Catalysts for Bristol-Myers Squibb Co

Bristol-Myers Squibb Co — navlimetostat (Phase I Trial Initiation)

ONUREG (AZACITIDINE) — FDA approval

KRAZATI (ADAGRASIB) — FDA approval

SOTYKTU (DEUCRAVACITINIB) — FDA approval

Liofilchem s.r.l. — MTS Aztreonam-Avibactam 0.016/4 - 256/4 µg/mL (510k cleared)

Beckman Coulter, Inc. — MicroScan Dried Gram-Negative MIC/Combo Panels with Aztreonam (AZT) (0.5-64 µg/mL) (510k cleared)

Biomérieux — ETEST Aztreonam/Avibactam (AZA) (0.016/4-256/4 µg/mL) (510k cleared)

Hardy Diagnostics — HardyDisk Aztreonam/Avibactam 30/20µg (AZA50) (510k cleared)

KRAZATI (ADAGRASIB) — FDA approval

KRAZATI (ADAGRASIB) — FDA approval

SOTYKTU (DEUCRAVACITINIB) — FDA approval

ONUREG (AZACITIDINE) — FDA approval

ONUREG (AZACITIDINE) — FDA approval

NCT07160725: A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

NCT07463768: Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.